Vigil Presents Data on its Small Molecule TREM2 Agonist Program at 2024 Alzheimer's Association International Conference (AAIC)
30 Julho 2024 - 5:05PM
Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage
biotechnology company committed to harnessing the power of
microglia for the treatment of neurodegenerative diseases, today
presented one oral and two poster presentations at the 2024
Alzheimer's Association International Conference (AAIC) being held
July 28 - August 1, 2024 in Philadelphia, Pennsylvania and
virtually.
“As the first company to advance a small
molecule TREM2 agonist into clinical development, we are excited to
present data from this important program at AAIC,” said David Gray,
Ph.D., Chief Science Officer at Vigil. “TREM2 has a strong causal
link to Alzheimer’s disease risk and the data shared today further
support our growing body of both preclinical and clinical findings
that VG-3927 is a potent molecule that functionally engages TREM2
receptors in the brain. According to the World Health Organization,
AD is the most common type of dementia, and we believe VG-3927 has
the potential to offer a differentiated approach to treating this
devastating disease.”
Oral presentation by Christian Mirescu,
Ph.D., Vigil Neuroscience: Orally Administered Small
Molecule TREM2 Agonists for Modulating AD Pathophysiology
The oral presentation highlighted new data from
the Company’s small molecule Triggering Receptor Expressed on
Myeloid Cells 2 (TREM2) Agonist program, including:
- In vivo data showing that Vigil’s
small molecule TREM2 agonist selectively activates downstream
function leading to microglial amyloid-beta (Aβ) phagocytosis.
- In vivo data from Vigil’s small
molecule TREM2 agonist program demonstrating acute modulation of AD
pathophysiology, comparable to an approved therapeutic, without
effector function liability.
- In vitro data from VG-3927
demonstrating preferential activity on cellular TREM2 establishing
sTREM2 as a target engagement biomarker linked to TREM2
signaling.
- Clinical data from single ascending
dose (SAD) cohorts in the ongoing Phase 1 trial evaluating VG-3927
showing a robust decrease of sTREM2 in the CSF demonstrating
proof-of-pharmacology.
Poster presentation by Raj Rajagovindan,
Ph.D., Vigil Neuroscience: Design of a Phase 1,
First-in-human, Randomized, Double-blind, Placebo-controlled,
Single- and Multiple-Ascending Dose Study of a Novel Orally
Administered TREM2 Agonist (VG-3927) in Healthy Volunteers
Poster details include:
- The Phase 1 clinical trial is a
randomized, double-blind, placebo-controlled, SAD/MAD study
evaluating the safety, tolerability, PK, and PD following oral
administration of VG-3927 in healthy volunteers.
- Cohorts are conducted sequentially
in a dose-escalating manner, and dosing may be adjusted based on
safety and tolerability assessments and emerging PK data.
- For each cohort, 8 participants are
randomized in a 6:2 allocation ratio to VG-3927 or placebo.
- Blood samples are collected in all
cohorts to characterize PK of VG-3927.
- Cerebrospinal fluid samples are
collected in select cohorts to investigate biomarkers of target
engagement.
Poster presentation by Borislav
Dejanovic, Ph.D., Vigil Neuroscience: Pharmacological and
Functional Characterization of the First Small Molecule TREM2
Agonist, VG-3927, for the Treatment of Alzheimer’s Disease
Poster details show that VG-3927:
- Is a TREM2 specific, highly potent
molecule that potentiates signaling from lipid ligands.
- Induces functional agonism via
unique clustering of TREM2 complexes in microglia.
- Activates protective gene
signatures in mouse model of amyloidosis.
- Suppresses pro-inflammatory
cytokines and protects against neurodegeneration in human CNS
triculture model.
The presentation and posters are available on
the Publications page of the Company’s website.
About Vigil Neuroscience
Vigil Neuroscience is a clinical-stage
biotechnology company focused on developing treatments for both
rare and common neurodegenerative diseases by restoring the
vigilance of microglia, the sentinel immune cells of the brain.
Vigil is utilizing the tools of modern neuroscience drug
development across multiple therapeutic modalities in its efforts
to develop precision-based therapies to improve the lives of
patients and their families. Iluzanebart, Vigil’s lead clinical
candidate, is a fully human monoclonal antibody agonist targeting
human triggering receptor expressed on myeloid cells 2 (TREM2) in
people with adult-onset leukoencephalopathy with axonal spheroids
and pigmented glia (ALSP), a rare and fatal neurodegenerative
disease. Vigil is also developing VG-3927, a novel small molecule
TREM2 agonist, to treat common neurodegenerative diseases
associated with microglial dysfunction, with an initial focus on
Alzheimer’s disease (AD) patients, including some who carry TREM2
and other disease-associated variants.
Forward-Looking
Statements This press release includes certain
disclosures that contain “forward-looking statements” of Vigil
Neuroscience (“Vigil” or the “Company”) that are made pursuant to
the safe harbor provisions of the federal securities laws,
including, without limitation, express or implied statements
regarding: Vigil’s strategy, business plans and focus; the
potential therapeutic benefit of our product candidates, including
VG-3927, and the expected therapeutic benefits of such programs;
VG-3927’s potential as a TREM2 agonist and its ability to convert
microglia into a neuroprotective state. Forward-looking statements
are based on Vigil’s current expectations and are subject to
inherent uncertainties, risks and assumptions that are difficult to
predict. Factors that could cause actual results to differ include,
but are not limited to, risks and uncertainties related to
uncertainties inherent in the development of product candidates,
including the conduct of research activities and the conduct of
clinical trials; whether results from preclinical studies and
clinical trials will be predictive of the results of later
preclinical studies and clinical trials; the timing and content of
additional regulatory interactions with the FDA – including the
Company’s discussions regarding the partial clinical hold on
VG-3927; as well as the risks and uncertainties identified in the
Company’s filings with the Securities and Exchange Commission
(SEC), including Vigil’s Quarterly Report on Form 10-Q for the
quarter ended March 31, 2024 and in any subsequent filings Vigil
makes with the SEC. Forward-looking statements contained in this
announcement are made as of this date, and Vigil undertakes no duty
to update such information except as required under applicable law.
Readers should not rely upon the information on this page as
current or accurate after its publication date.
Internet Posting of
Information Vigil Neuroscience routinely posts
information that may be important to investors in the 'Investors'
section of its website at https://www.vigilneuro.com. The company
encourages investors and potential investors to consult our website
regularly for important information about Vigil
Neuroscience.
Investor Contact: Leah
Gibson Vice President, Investor Relations &
Corporate Communications Vigil Neuroscience,
Inc. lgibson@vigilneuro.com Media
Contact: Megan McGrathCTD Comms,
LLCmegan@ctdcomms.com
Vigil Neuroscience (NASDAQ:VIGL)
Gráfico Histórico do Ativo
De Jul 2024 até Ago 2024
Vigil Neuroscience (NASDAQ:VIGL)
Gráfico Histórico do Ativo
De Ago 2023 até Ago 2024